ArcherDX addresses the bottlenecks associated with using next-generation sequencing in translational research by offering a robust platform for targeted sequencing applications.

By combining proprietary Anchored Multiplexed PCR (AMP) chemistry and easy-to-use, lyophilized reagents, ArcherDX technology generates highly enriched sequencing libraries to detect gene fusions, SNPs, indels and CNVs. Complemented by the Archer suite of bioinformatics software and readily accessible reports, ArcherDX technology dramatically enhances complex mutation identification and discovery.

ArcherDX is headquartered in Boulder, Colorado.